Awareness of Emerging Novel Epigenetic Targeting Therapy in Acute Myeloid Leukemia

Nahla AM Hamed
Additional contact information
Nahla AM Hamed: Hematology Department, Alexandria University, Egypt

Cancer Therapy & Oncology International Journal, 2018, vol. 11, issue 3, 86-88

Abstract: Many of the recurrently mutated genes in AML may affect epigenetic regulators of transcription. Epigenetic modifiers represent a major focus of interest and are highlighted as attractive targets for personalized therapy in AML. Some novel agents showed encouraging clinical activity in early phase trials while other agents (e.g., EZH2 inhibitors) are in early preclinical development and will likely be tested in AML trials in the near future. Many novel agents in development target niche areas for AML leukemogenesis including the epigenetic regulators BET proteins, DOT1L, and LSD1 which are suggested to have a role in MLL-r AML and possibly other subsets.

Keywords: juniper publishers:oncology journals; oncology research journals; oncology journal articles; oncology and cancer case reports; oncology journal of clinical and experimental cancer research; open access; open access journals; Oncology International Journal; juniper publishers reivew (search for similar items in EconPapers)
Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.555815.pdf (application/pdf)
https://juniperpublishers.com/ctoij/CTOIJ.MS.ID.555815.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jctoij:v:11:y:2018:i:3:p:86-88

DOI: 10.19080/CTOIJ.2018.11.555815

Access Statistics for this article

Cancer Therapy & Oncology International Journal is currently edited by Sophia Mathis

More articles in Cancer Therapy & Oncology International Journal from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().